[go: up one dir, main page]

WO2011150201A3 - Azolyl amide compounds and methods of use thereof - Google Patents

Azolyl amide compounds and methods of use thereof Download PDF

Info

Publication number
WO2011150201A3
WO2011150201A3 PCT/US2011/038129 US2011038129W WO2011150201A3 WO 2011150201 A3 WO2011150201 A3 WO 2011150201A3 US 2011038129 W US2011038129 W US 2011038129W WO 2011150201 A3 WO2011150201 A3 WO 2011150201A3
Authority
WO
WIPO (PCT)
Prior art keywords
azolyl
methods
amide compounds
compounds
amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/038129
Other languages
French (fr)
Other versions
WO2011150201A2 (en
Inventor
Gang Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ambit Bioscience Corp
Original Assignee
Ambit Bioscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambit Bioscience Corp filed Critical Ambit Bioscience Corp
Publication of WO2011150201A2 publication Critical patent/WO2011150201A2/en
Publication of WO2011150201A3 publication Critical patent/WO2011150201A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Provided herein are azolyl amide compounds for treatment of CSF-1R kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
PCT/US2011/038129 2010-05-27 2011-05-26 Azolyl amide compounds and methods of use thereof Ceased WO2011150201A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34912810P 2010-05-27 2010-05-27
US61/349,128 2010-05-27

Publications (2)

Publication Number Publication Date
WO2011150201A2 WO2011150201A2 (en) 2011-12-01
WO2011150201A3 true WO2011150201A3 (en) 2012-05-03

Family

ID=44509738

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/038129 Ceased WO2011150201A2 (en) 2010-05-27 2011-05-26 Azolyl amide compounds and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2011150201A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107624110A (en) * 2015-03-06 2018-01-23 法玛克亚公司 Inhibitor of lysyloxidase sample 2 and application thereof

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX389256B (en) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc HETEROCYCLIC COMPOUNDS AND THEIR USES.
EA201691872A1 (en) 2014-03-19 2017-04-28 Инфинити Фармасьютикалз, Инк. HETEROCYCLIC COMPOUNDS FOR APPLICATION IN THE TREATMENT OF PI3K-GAMMA-MEDIATED DISORDERS
WO2015187818A1 (en) * 2014-06-03 2015-12-10 The Arizona Board Of Regents On Behalf Of The University Of Arizona Benzimidazole analogues and related methods
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3795568A1 (en) 2015-03-06 2021-03-24 Pharmakea, Inc. Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
CN108349985A (en) 2015-09-14 2018-07-31 无限药品股份有限公司 Solid forms of isoquinolinones, processes for their preparation, compositions containing them and methods of their use
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP7097874B2 (en) 2016-09-07 2022-07-08 ファーマケア，インク． Use of lysyl oxidase-like 2 inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261315A1 (en) * 2003-11-13 2005-11-24 Ambit Biosciences Corporation Amide derivatives as kinase modulators

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
DE3209472C2 (en) 1982-03-16 1984-05-17 Degussa Ag, 6000 Frankfurt Process for the preparation of 3-oxonitriles and new 3-oxonitriles
KR890002631B1 (en) 1984-10-04 1989-07-21 몬산토 캄파니 Composition of prolonged release of biologically active somatotropin
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
JPS6296479A (en) 1985-10-23 1987-05-02 Shionogi & Co Ltd Polyfluoroalkylisoxazolylamine
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (en) 1989-03-22 1991-07-25 Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (en) 1990-04-17 1994-11-18 Eurand Int METHOD FOR THE TARGETED AND CONTROLLED DELIVERY OF DRUGS IN THE INTESTINE AND PARTICULARLY IN THE COLON
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1270594B (en) 1994-07-07 1997-05-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
DE69632684T2 (en) 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. PROCESS FOR PREPARING PREPARED DELETION PREPARATIONS
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (en) 1995-09-18 1999-06-23 株式会社資生堂 Delayed release microsphere of drug
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
US6139865A (en) 1996-10-01 2000-10-31 Eurand America, Inc. Taste-masked microcapsule compositions and methods of manufacture
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
EP0839525B1 (en) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
DK0946169T3 (en) 1996-12-20 2003-04-22 Takeda Chemical Industries Ltd Process for the preparation of a sustained release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6740634B1 (en) 1998-01-16 2004-05-25 Takeda Chemical Industries, Ltd. Sustained release compositions, process for producing the same and utilization thereof
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (en) 1998-05-16 1999-12-06 허영섭 Biodegradable polymer microspheres capable of continuously controlled controlled release and preparation method thereof
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US7112435B1 (en) 2002-08-07 2006-09-26 Ambit Biosciences Corporation Uncoupling of DNA insert propagation and expression of protein for phage display
KR20090034930A (en) 2006-06-30 2009-04-08 암비트 바이오사이언시즈 코포레이션 Detectable Nucleic Acid Tags

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261315A1 (en) * 2003-11-13 2005-11-24 Ambit Biosciences Corporation Amide derivatives as kinase modulators

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107624110A (en) * 2015-03-06 2018-01-23 法玛克亚公司 Inhibitor of lysyloxidase sample 2 and application thereof
CN107624110B (en) * 2015-03-06 2021-01-26 法玛克亚公司 Lysyl oxidase-like 2 inhibitors and uses thereof

Also Published As

Publication number Publication date
WO2011150201A2 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
WO2011150201A3 (en) Azolyl amide compounds and methods of use thereof
EP4406950A3 (en) Lfa-1 inhibitor and polymorph thereof
MX2012001974A (en) Biaryl compounds and methods of use thereof.
WO2012055567A3 (en) Use of malononitrilamides in neuropathic pain
WO2011153514A9 (en) The use of inhibitors of bruton's tyrosine kinase (btk)
WO2012030993A3 (en) Skin compositions and methods of use thereof
IL216399A0 (en) Pharmaceutical composition for the treatment of heart diseases
GB2479213B (en) Pharmaceutical formulations for the treatment of overactive bladder
IL224544B (en) Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
IL214396A (en) Carba-nucleosides for antiviral treatment, pharmaceutical compositions comprising the same and methods of making carba-nucleosides and intermediates of carba-nucleosides for antiviral treatment
LT2925757T (en) Compounds and compositions for the treatment of parasitic diseases
HK1206726A1 (en) Imidazotriazinone compounds
IN2014CN03597A (en)
IL208357A0 (en) Spiro-indole derivatives for the treatment of parasitic diseases
IL211313A0 (en) Compounds, compositions and methods for the treatment of ??-amyloid diseases and synucleinopathies
ZA201200944B (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
WO2011150190A3 (en) Hcv inhibitor compounds and methods of use thereof
PL2331092T3 (en) Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer
HK1216721A1 (en) Uses and methods for the treatment of liver diseases or conditions
EP2785335B8 (en) Methods and pharmaceutical compositions for the treatment of darier disease
EP2590651B8 (en) New drug combinations for the treatment of malaria
EP2575926B8 (en) Apparatus for the treatment of the blood
HK1178164A (en) Compositions and methods for the treatment of degenerative diseases
HK1182942A (en) Formulations of quinones for the treatment of ophthalmic diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11727360

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11727360

Country of ref document: EP

Kind code of ref document: A2